ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-05-28
DOI
https://doi.org/10.1200/jco.2025.43.16_suppl.tps4630
Citations
2
Primary Topic
Cancer Treatment and Pharmacology
Type
article
Field-Weighted Citation Impact
2.09
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study.

Joshua J. Meeks, Girish S. Kulkarni, Wassim Kassouf, Jørn S. Jakobsen et al.
2 citations
Journal of Clinical Oncology
Cancer Treatment and Pharmacology
2.09
article

ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study.

Joshua J. Meeks, Girish S. Kulkarni, Wassim Kassouf, Jørn S. Jakobsen, Yair Lotan, Siamak Daneshmand, Peter Albers, Trinity J. Bivalacqua, Stephen A. Boorjian, Kristian Vinter Juul, Paolo Gontero
article en
2 citations

Abstract

No abstract available for this paper.
Journal of Clinical OncologyVol. 43(16_suppl)
Northwestern University (US), University Health Network (CA), Mayo Clinic (US), Hospital of the University of Pennsylvania (US), Keck Hospital of USC (US), McGill University Health Centre (CA), WinnMed (US), Princess Margaret Cancer Centre (CA), Southwestern Medical Center (US), Ferring Pharmaceuticals (Denmark) (DK), Southwestern Medical Center (US), Heinrich Heine University Düsseldorf (DE), University of Turin (IT), The University of Texas Southwestern Medical Center (US)
Openalex Percentile: Top 12%
Cancer Treatment and Pharmacology
2.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study. — Joshua J. Meeks, Girish S. Kulkarni, et al. · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS